PD-L1 is a protein that plays an important role in regulating the immune system, but some cancer cells take advantage of this natural mechanism to escape immune detection. Our lead compound, NDL2, is an optimized bicyclic peptide designed to selectively degrade disease-associated nuclear PD-L1 protein and restore the body’s natural anti-tumor immune response.
| Study / Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | Sponsor |
|---|---|---|---|---|---|---|
| Advanced Solid Tumors |
|
|
|
|
|
Kazia Therapeutics |
NDL2 selectively targets nuclear PD-L1 protein pools that are enriched in cancer cells and inaccessible to conventional checkpoint inhibitors. By recruiting the cell’s natural degradation machinery, it promotes the clearance of these intracellular tumor-specific PD-L1 protein, offering a mechanism to enhance immune-mediated tumor control.
Targeted Protein Degradation (TPD) therapies opened a new frontier for treating cancer by exploiting naturally occurring protein degradation pathways to disrupt critical cellular processes.
As a first-in-class therapy, NDL2 is advancing within a new scientific category, PD-L1 degradation, with no other compounds yet in clinical development.
Explore our posters and publications to access our latest scientific data, clinical insights, and contributions to advancing oncology research.
View Our Posters & Publications